Spooky action at a distance: neuromodulation, physiologic distress signals, and limb preservation

Abstract

The rising global prevalence of chronic conditions, notably obesity and type 2 diabetes, demands innovative approaches to mitigate their health and economic impacts. Complications, including neuropathy and chronic limb-threatening ischemia (CLTI), dramatically increase the risk of lower limb amputation, cardiovascular events, and cerebrovascular events, underscoring the urgent need for effective interventions. Emerging neuromodulation and regenerative strategies provide novel approaches to addressing diabetes-related complications. High-frequency (10-kHz) spinal cord stimulation demonstrates marked pain relief and sensory improvement in patients with refractory painful diabetic neuropathy. Peripheral focused ultrasound, including splenic-targeted stimulation, shows promise in reducing systemic inflammation, accelerating wound repair, and enhancing vascular function. Remote ischemic conditioning leverages brief controlled ischemic reperfusion cycles to enhance microcirculation and promote diabetic foot ulcer (DFU) healing. In severe cases, surgical techniques such as tibial transverse transport and lateral tibial periosteum distraction stimulate angiogenesis and enhance distal limb perfusion. Integrated wound care protocols, incorporating these procedures alongside debridement, negative pressure wound therapy, and skin grafting, may further optimize outcomes. Collectively, these therapies address both local and systemic pathophysiology, frequently producing physiologic effects at sites distant from the primary intervention. These seemingly disparate therapies represent a single unifying concept: generating a physiologic effect at locations remote from the primary target. This systematic approach, engaging neural, vascular, and immune pathways, may be key to improving outcomes in DFUs and CLTI. Early clinical data appears promising; however, larger randomized trials are required to validate efficacy, refine patient selection, and determine optimal integration with standard care. If confirmed, these strategies may shift management toward patient-centered, regenerative interventions that preserve limbs, reduce recurrence, and enhance quality of life for the expanding global patient population. Further research is warranted to confirm or refute these early promising physiologic effects.

Keywords

Diabetic foot ulcer / Chronic limb-threatening ischemia / Neuromodulation / Remote ischemic conditioning / Angiogenesis / Limb preservation

References

[1] Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of type 2 diabetes-global burden of disease and forecasted trends. J Epidemiol Glob Health 2020; 10: 107-11. https://doi.org/10.2991/jegh.k.191028.001.

[2] Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic foot ulcers: a review. JAMA 2023; 330: 62-75. https://doi.org/10.1001/jama.2023.10578.

[3] Centers for Disease Control and Prevention (CDC) . National Diabetes Statistics Report 2024: Estimates of Diabetes and Its Burden in the United States. Atlanta, GA: U.S. Department of Health and Human Services; 2024. Available from: https://www.cdc.gov/diabetes/php/data-research/index.html. Accessed November 27, 2025.

[4] Fermawi SA, Tolson JP, Knapp SM, Marrero D, Zhou W, Armstrong DG, et al. Disparities in preventative diabetic foot examination. Semin Vasc Surg 2023; 36: 84-9. https://doi.org/10.1053/j.semvascsurg.2023.01.001.

[5] Clayton EO, Njoku-Austin C, Scott DM, Cain JD, Hogan MV. Racial and ethnic disparities in the management of diabetic feet. Curr Rev Musculoskelet Med 2023; 16: 550-6. https://doi.org/10.1007/s12178-023-09867-7.

[6] International Diabetes Federation (IDF) . Diabetes facts and figures. Brussels, Belgium: International Diabetes Federation; 2024. Available from: https://idf.org/about-diabetes/diabetes-facts-figures/. Accessed November 27, 2025.

[7] Obesity and overweight. Accessed November 27, 2025. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

[8] Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, et al. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Sig Transduct Target Ther 2024; 9: 262. https://doi.org/10.1038/s41392-024-01951-9.

[9] Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol 2022; 18: 525-39. https://doi.org/10.1038/s41574-022-00690-7.

[10] Lepäntalo M, Apelqvist J, Setacci C, Ricco JB, de Donato G, Becker F, et al. Chapter V: diabetic foot. Eur J Vasc Endovasc Surg 2011; 42: S60-74. https://doi.org/10.1016/S1078-5884(11)60012-9.

[11] Thukkani AK, Kinlay S. Endovascular intervention for peripheral artery disease. Circ Res 2015; 116: 1599-613. https://doi.org/10.1161/CIRCRESAHA.116.303503.

[12] Deng L, Du C, Liu L, Wang Y, Gu H, Armstrong DG, et al. Forecasting the global burden of peripheral artery disease from 2021 to 2050: a population-based study. Research (Wash D C) 8: 0702. https://doi.org/10.34133/research.0702.

[13] Rankin TM, Miller JD, Gruessner AC, Nickerson DS. Illustration of cost saving implications of lower extremity nerve decompression to prevent recurrence of diabetic foot ulceration. J Diabetes Sci Technol 2015; 9: 873-80. https://doi.org/10.1177/1932296815584796.

[14] Jia L, Parker CN, Parker TJ, Kinnear EM, Derhy PH, Alvarado AM, et al. Incidence and risk factors for developing infection in patients presenting with uninfected diabetic foot ulcers. PLoS One 2017; 12: e0177916. https://doi.org/10.1371/journal.pone.0177916.

[15] Kim SY, Kim TH, Choi JY, Kwon YJ, Choi DH, Kim KC, et al. Predictors for amputation in patients with diabetic foot wound. Vasc Specialist Int 2018; 34: 109-16. https://doi.org/10.5758/vsi.2018.34.4.109.

[16] Fife CE, Eckert KA, Carter MJ. Publicly reported wound healing rates: the fantasy and the reality. Adv Wound Care (New Rochelle) 2018; 7: 77-94. https://doi.org/10.1089/wound.2017.0743.

[17] Zimny S, Schatz H, Pfohl M. Determinants and estimation of healing times in diabetic foot ulcers. J Diabetes Complicat 2002; 16: 327-32. https://doi.org/10.1016/s1056-8727(01)00217-3.

[18] Armstrong NS, Armstrong AA, Mills JL, Conte MS, Tan TW, Swanson RS, et al. Three-year recurrence in people with diabetic foot ulcers and chronic limb threatening ischemia is comparable to cancer. Int Wound J 2025; 22: e70724. https://doi.org/10.1111/iwj.70724.

[19] Fu XL, Ding H, Miao WW, Mao CX, Zhan MQ, Chen HL. Global recurrence rates in diabetic foot ulcers: a systematic review and meta-analysis. Diabetes Metab Res Rev 2019; 35: e3160. https://doi.org/10.1002/dmrr.3160.

[20] Zanos S, Ntiloudi D, Pellerito J, Ramdeo R, Graf J, Wallace K, et al. Focused ultrasound neuromodulation of the spleen activates an anti-inflammatory response in humans. Brain Stimul 2023; 16: 703-11. https://doi.org/10.1016/j.brs.2023.04.003.

[21] Cotero V, Graf J, Zachs DP, Tracey KJ, Ashe J, Lim HH, et al. Peripheral focused ultrasound stimulation (pFUS): new competitor in pharmaceutical markets? SLAS Technol 2019; 24: 448-52. https://doi.org/10.1177/2472630319849383.

[22] Hess DC, Hoda MN, Khan MB. Humoral mediators of remote ischemic conditioning: important role of eNOS/NO/nitrite. Acta Neurochir Suppl 2016; 121: 45-8. https://doi.org/10.1007/978-3-319-18497-5_8.

[23] Regulski M, Greenwood T, Leschinsky B. Impact of repeated remote ischemic conditioning on diabetic foot ulcers: a proof-of-concept study. Wound Repair Regen 2021; 29: 853-8. https://doi.org/10.1111/wrr.12956.

[24] Shaked G, Czeiger D, Abu Arar A, Katz T, Harman-Boehm I, Sebbag G. Intermittent cycles of remote ischemic preconditioning augment diabetic foot ulcer healing. Wound Repair Regen 2015; 23: 191-6. https://doi.org/10.1111/wrr.12269.

[25] Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017; 376: 2367-75. https://doi.org/10.1056/NEJMra1615439.

[26] PAIN Reports. Accessed November 27, 2025. https://journals.lww.com/painrpts/fulltext/2025/02000/characterization_of_preclinical_models_to.20.aspx.

[27] Chen Y, Ding X, Zhu Y, Jia Z, Qi Y, Chen M, et al. Effect of tibial cortex transverse transport in patients with recalcitrant diabetic foot ulcers: a prospective multicenter cohort study. J Orthop Translat 2022; 36: 194-204. https://doi.org/10.1016/j.jot.2022.09.002.

[28] Petersen EA, Stauss TG, Scowcroft JA, Brooks ES, White JL, Sills SM, et al. Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial. JAMA Neurol 2021; 78: 687-98. https://doi.org/10.1001/jamaneurol.2021.0538.

[29] Cotero V, Fan Y, Tsaava T, Kressel AM, Hancu I, Fitzgerald P, et al. Noninvasive sub-organ ultrasound stimulation for targeted neuromodulation. Nat Commun 2019; 10: 952. https://doi.org/10.1038/s41467-019-08750-9.

[30] Cotero V, Miwa H, Graf J, Ashe J, Loghin E, di Carlo D, et al. Peripheral focused ultrasound neuromodulation (pFUS). J Neurosci Methods 2020; 341: 108721. https://doi.org/10.1016/j.jneumeth.2020.108721.

[31] Liu JT, Su CH, Chen SY, Liew SJ, Chang CS. Spinal cord stimulation improves the microvascular perfusion insufficiency caused by critical limb ischemia. Neuromodulation 2018; 21: 489-94. https://doi.org/10.1111/ner.12753.

[32] Cyrek AE, Koch D, Pacha A, Radunz S. Effectiveness of spinal cord stimulation in diabetic patients with chronic limb-threatening ischemia: small cohort study. Front Surg 2024; 11: 1451622. https://doi.org/10.3389/fsurg.2024.1451622.

[33] GE HealthCare and Novo Nordisk to Collaborate to Advance Novel Non-invasive Treatment for Type 2 Diabetes and Obesity with Ultrasound | GE HealthCare (United States). Accessed November 27, 2025. https://www.gehealthcare.com/about/newsroom/press-releases/ge-healthcare-and-novo-nordisk-to-collaborate-to-advance-novel-non-invasive-treatment-for-type-2-diabetes-and-obesity-with-ultrasound?srsltid=AfmBOoosBTLU0BDvIAwcfMJflkXCQfqv28qlW6qALllrXc0ANrlBoWa-).

[34] Zanos S, Silverman HA, Levy T, Tsaava T, Battinelli E, Lorraine PW, et al. Identification of cytokine-specific sensory neural signals by decoding murine vagus nerve activity. Proc Natl Acad Sci USA 2018; 115: E4843-52. https://doi.org/10.1073/pnas.1719083115.

[35] Boghossian JA, Joseph B, Slepian MJ, Armstrong DG. Remote ischemic conditioning promising potential in wound repair in diabetes? J Am Podiatr Med Assoc 2017; 107: 313-7. https://doi.org/10.7547/15-172.

[36] Kong L, Li Y, Deng Z, Chen X, Xia Y, Shen B, et al. Tibial cortex transverse transport regulates Orai1/STIM1-mediated NO release and improve the migration and proliferation of vessels via increasing osteopontin expression. J Orthop Translat 2024; 45: 107-19. https://doi.org/10.1016/j.jot.2024.02.007.

[37] Wen Y, Chen L, Lan J, Li L. Efficacy of tibial cortex transverse transport in treating diabetic foot ulcer and its effect on serum omentin-1 and irisin levels. Diabetol Metab Syndr 2024; 16: 154. https://doi.org/10.1186/s13098-024-01400-1.

[38] Zhao S, Guo F, Zang Y, Hu R, Yu X, Zhang H, et al. The association of the perioperative neutrophil-to-lymphocyte ratio with wound healing in patients with Wagner grade 3 and 4 diabetic foot ulcers after tibial cortex transverse transport surgery: a prospective observational cohort study. Front Endocrinol (Lausanne) 2024; 15: 1420232. https://doi.org/10.3389/fendo.2024.1420232.

[39] Verrills P, Sinclair C, Barnard A. A review of spinal cord stimulation systems for chronic pain. J Pain Res 2016; 9: 481-92. https://doi.org/10.2147/JPR.S108884.

[40] Zhao D, Wang Y, Han D. Periosteal distraction osteogenesis: an effective method for bone regeneration. Biomed Res Int 2016; 2016: 1-10. https://doi.org/10.1155/2016/2075317.

[41] Yang Y, Chen F, Chen Y, Wang W. Comparison of the efficacy of tibial transverse transfer and periosteal distraction techniques in the treatment of diabetic foot refractory ulcers. Front Surg 2024; 11: 1396897. https://doi.org/10.3389/fsurg.2024.1396897.

[42] Zakaria O, Madi M, Kasugai S. Induced osteogenesis using a new periosteal distractor. J Oral Maxillofac Surg 2012; 70: e225-34. https://doi.org/10.1016/j.joms.2011.10.032.

[43] Yang R, Zhou Y, Hu Y, Liu S. Periosteal distraction as a new surgical technique for the treatment of senile diabetic foot: a retrospective case analysis. Medicine (Baltimore) 2025; 104: e41183. https://doi.org/10.1097/MD.0000000000041183.

[44] Heusch G, Bøtker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. J Am Coll Cardiol 2015; 65: 177-95. https://doi.org/10.1016/j.jacc.2014.10.031.

[45] Wang J, Huang X, Wang P, Zhang J, Yu Y, Chen X. Periosteal distraction for foot preservation contributes to favorable clinical effects and prognosis in a foot ulcer patient with critical limb ischemia after multiple operations. Am J Transl Res 2023; 15: 3766-72.

[46] Deer TR, Mekhail N, Provenzano D, Pope J, Krames E, Leong M, et al. The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: the neuromodulation appropriateness consensus committee. Neuromodulation 2014; 17: 515-50; discussion 550. https://doi.org/10.1111/ner.12208.

[47] Karcz M, Abd-Elsayed A, Chakravarthy K, Mansoor A, Strand N, Malinowski M, et al. Pathophysiology of pain and mechanisms of neuromodulation: a narrative review (a neuron project). J Pain Res 2024; 17: 3757-90. https://doi.org/10.2147/JPR.S475351.

[48] Rauck RL, Loudermilk E, Thomson SJ, Paz-Solis JF, Bojrab L, Noles J, et al. Long-term safety of spinal cord stimulation systems in a prospective, global registry of patients with chronic pain. Pain Manag 2023; 13: 115-27. https://doi.org/10.2217/pmt-2022-0091.

[49] Pluijms WA, Slangen R, Joosten EA, Kessels AG, Merkies IS, Schaper NC, et al. Electrical spinal cord stimulation in painful diabetic polyneuropathy, a systematic review on treatment efficacy and safety. Eur J Pain 2011; 15: 783-8. https://doi.org/10.1016/j.ejpain.2011.01.010.

[50] Maiya AG, Kumar AS, Hazari A, Jadhav R, Ramachandra L, Hande HM, et al. Photobiomodulation therapy in neuroischaemic diabetic foot ulcers: a novel method of limb salvage. J Wound Care 2018; 27: 837-42. https://doi.org/10.12968/jowc.2018.27.12.837.

[51] Matija D, Ivan D, Andrea CG, Majda VK, Likic R . Cold atmospheric plasma therapy for diabetic foot ulcers: a systematic review and meta-analysis of randomised controlled trials. Int J Low Extrem Wounds. Published online November 20, 2025. https://doi.org/10.1177/15347346251395904.

[52] Chen SZ, Takahashi T, Lai HJ, Su HH, Cheng YJ. Therapeutic effects of photobiomodulation combined with exercise on patients with peripheral artery disease plus diabetic foot ulcer: a pilot and feasibility study. Life (Basel) 2025; 15: 1391. https://doi.org/10.3390/life15091391.

[53] Mirpour S, Fathollah S, Mansouri P, Larijani B, Ghoranneviss M, Mohajeri Tehrani MR, et al. Cold atmospheric plasma as an effective method to treat diabetic foot ulcers: a randomized clinical trial. Sci Rep 2020; 10: 10440. https://doi.org/10.1038/s41598-020-67232-x.

[54] Rathnayake A, Saboo A, Vangaveti V, Malabu U. Electromechanical therapy in diabetic foot ulcers patients: a systematic review and meta-analysis. J Diabetes Metab Disord 2023; 22: 967-84. https://doi.org/10.1007/s40200-023-01240-2.

[55] Patel N, Calodney A, Kapural L, Province-Azalde R, Lad SP, Pilitsis J, et al. High-frequency spinal cord stimulation at 10 kHz for the treatment of nonsurgical refractory back pain: design of a pragmatic, multicenter. Pain Pract 2021; 21: 171-83. https://doi.org/10.1111/papr.12945.

[56] Sears NC, Machado AG, Nagel SJ, Deogaonkar M, Stanton-Hicks M, Rezai AR, et al. Long-term outcomes of spinal cord stimulation with paddle leads in the treatment of complex regional pain syndrome and failed back surgery syndrome. Neuromodulation 2011; 14: 312-8; discussion 318. https://doi.org/10.1111/j.1525-1403.2011.00372.x.

[57] Racine M. Chronic pain and suicide risk: a comprehensive review. Prog Neuro-Psychopharmacol Biol Psychiatry 2018; 87: 269-80. https://doi.org/10.1016/j.pnpbp.2017.08.020.

[58] Dueñas M, Ojeda B, Salazar A, Mico JA, Failde I. A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res 2016; 9: 457-67. https://doi.org/10.2147/JPR.S105892.

[59] Luecke T, Edgar D, Huse D. 10 kHz spinal cord stimulation for the treatment of chronic back and/or leg pain: summary of clinical studies. SAGE Open Med 2020; 8: 2050312120951369. https://doi.org/10.1177/2050312120951369.

[60] Reid KJ, Harker J, Bala MM, Truyers C, Kellen E, Bekkering GE, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin 2011; 27: 449-62. https://doi.org/10.1185/03007995.2010.545813.

[61] Social cost of chronic pain in Italy: Il costo sociale del dolore cronico in Italia | Global and Regional Health Technology Assessment. Accessed November 28, 2025. https://journals.aboutscience.eu/index.php/grhta/article/view/322.

[62] Gharibo C, Laux G, Forzani BR, Sellars C, Kim E, Zou S. State of the field survey: spinal cord stimulator use by academic pain medicine practices. Pain Med 2014; 15: 188-95. https://doi.org/10.1111/pme.12264.

[63] Moore DM, McCrory C. Spinal cord stimulation. BJA Educ 2016; 16: 258-63. https://doi.org/10.1093/bjaed/mkv072.

[64] Systematic review of the (cost-)effectiveness of spinal cord stimulation for people with failed back surgery syndrome-PubMed. Accessed November 28, 2025. https://pubmed.ncbi.nlm.nih.gov/18936591/.

[65] Russo M, Van Buyten JP. 10-kHz high-frequency SCS therapy: a clinical summary. Pain Med 2015; 16: 934-42. https://doi.org/10.1111/pme.12617.

[66] Kreis PG. Spinal Cord Stimulation: Percutaneous Implantation Techniques. Oxford, UK: Oxford University Press; 2009.

[67] Tieppo Francio V, Polston KF, Murphy MT, Hagedorn JM, Sayed D . Management of chronic and neuropathic pain with 10 kHz spinal cord stimulation technology: summary of findings from preclinical and clinical studies. Biomedicines 2021; 9: 644. https://doi.org/10.3390/biomedicines9060644.

[68] Petersen EA, Stauss TG, Scowcroft JA, Jaasma MJ, Brooks ES, Edgar DR, et al. Long-term efficacy of high-frequency (10 kHz) spinal cord stimulation for the treatment of painful diabetic neuropathy: 24-month results of a randomized controlled trial. Diabetes Res Clin Pract 2023; 203: 110865. https://doi.org/10.1016/j.diabres.2023.110865.

[69] Farber SH, Han JL, Elsamadicy AA, Hussaini Q, Yang S, Pagadala P, et al. Long-term cost utility of spinal cord stimulation in patients with failed back surgery syndrome. Pain Physician 2017; 20: E797-805. https://doi.org/10.36076/ppj.20.5.E797.

[70] Mekhail NA, Argoff CE, Taylor RS, Nasr C, Caraway DL, Gliner BE, et al. High-frequency spinal cord stimulation at 10 kHz for the treatment of painful diabetic neuropathy: design of a multicenter, randomized controlled trial (SENZA-PDN). Trials 2020; 21: 87. https://doi.org/10.1186/s13063-019-4007-y.

[71] Argoff CE, Armstrong DG, Kagan ZB, Jaasma MJ, Bharara M, Bradley K, et al. Improvement in protective sensation: clinical evidence from a randomized controlled trial for treatment of painful diabetic neuropathy with 10 kHz spinal cord stimulation. J Diabetes Sci Technol 2025; 19: 992-8. https://doi.org/10.1177/19322968231222271.

[72] Hunter CW, Raskin JS, Mekhail NA, Petersen EA, Lad SP, Pope JE, et al. ECAP-controlled closed-loop spinal cord stimulation for chronic nonsurgical refractory back pain. Spine (Phila Pa 1976) 2025; 50: 1637-47. https://doi.org/10.1097/BRS.0000000000005445.

[73] Nonsurgical Back Pain. Accessed November 28, 2025. https://www.neuromodulation.abbott/us/en/healthcare-professionals/hcp-chronic-pain/scs-nsbp.html.

[74] Spinal Cord and Dorsal Root Ganglion Stimulation | Providers | Blue Cross NC. Accessed November 28, 2025. https://www.bluecrossnc.com/providers/policies-guidelines-codes/commercial/surgery/updates/spinal-cord-and-dorsal-root-ganglion-stimulation.

[75] Abbott Medical Devices . Dorsal spinal cord stimulation vs medical management for the treatment of low back pain (DISTINCT). ClinicalTrials.gov Identifier: NCT04479787. Bethesda (MD): National Library of Medicine (US). Available from: https://clinicaltrials.gov/study/NCT04479787. Accessed November 28, 2025. This is the standard biomedical citation format for ClinicalTrials.gov entries.

[76] Abbott Laboratories. Abbott receives FDA approval for its spinal cord stimulation systems to treat chronic back pain in people who have limited surgical options. Abbott MediaRoom. Abbott Park, IL, USA: Abbott Laboratories ; May 16, 2023. Available from: https://abbott.mediaroom.com/2023-05-16-Abbott-Receives-FDA-Approval-for-Its-Spinal-Cord-Stimulation-Systems-to-Treat-Chronic-Back-Pain-in-People-Who-Have-Limited-Surgical-Options. Accessed November 28, 2025.

[77] Ehde DM, Dillworth TM, Turner JA. Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research. Am Psychol 2014; 69: 153-66. https://doi.org/10.1037/a0035747.

[78] Deer T, Gilligan C, Falowski S, Desai M, Pilitsis J, Jameson J, et al. Treatment of refractory low back pain using passive recharge burst in patients without options for corrective surgery: findings and results from the DISTINCT study, a prospective randomized multicenter controlled trial. Neuromodulation 2023; 26: 1387-99. https://doi.org/10.1016/j.neurom.2023.07.009.

[79] Bao SC, Li F, Xiao Y, Niu L, Zheng H. Peripheral focused ultrasound stimulation and its applications: from therapeutics to human-computer interaction. Front Neurosci 2023; 17: 1115946. https://doi.org/10.3389/fnins.2023.1115946.

[80] Gigliotti JC, Huang L, Ye H, Bajwa A, Chattrabhuti K, Lee S, et al. Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway. J Am Soc Nephrol 2013; 24: 1451-60. https://doi.org/10.1681/ASN.2013010084.

[81] Cotero V, Graf J, Miwa H, Hirschstein Z, Qanud K, Huerta TS, et al. Stimulation of the hepatoportal nerve plexus with focused ultrasound restores glucose homoeostasis in diabetic mice, rats and swine. Nat Biomed Eng 2022; 6: 683-705. https://doi.org/10.1038/s41551-022-00870-w.

[82] Huerta TS, Devarajan A, Tsaava T, Rishi A, Cotero V, Puleo C, et al. Targeted peripheral focused ultrasound stimulation attenuates obesity-induced metabolic and inflammatory dysfunctions. Sci Rep 2021; 11: 5083. https://doi.org/10.1038/s41598-021-84330-6.

[83] Raihane AS, Armstrong DG, Gillenwater TJ, Galiano RD. Advancing therapeutic solutions for burn wounds: potential use of noninvasive ultrasound-driven splenic stimulation. Adv Wound Care (New Rochelle). Published online March 27, 2025. https://doi.org/10.1089/wound.2024.0181.

[84] Ultrasound Treatment on Wound Healing Time | Clinical Research Trial Listing. Accessed November 28, 2025. https://www.centerwatch.com/clinical-trials/listings/NCT05796492/ultrasound-treatment-on-wound-healing-time/ultrasound-treatment-on-wound-healing-time.

[85] Morton C, Cotero V, Ashe J, Ginty F, Puleo C. Accelerating cutaneous healing in a rodent model of type II diabetes utilizing non-invasive focused ultrasound targeted at the spleen. Front Neurosci 2022; 16: 1039960. https://doi.org/10.3389/fnins.2022.1039960.

[86] Efficacy of Long-Term Remote Ischemic Conditioning on Vascular and Neuronal Function in Type 2 Diabetes Patients With Peripheral Arterial Disease- PubMed. Accessed November 28, 2025. https://pubmed.ncbi.nlm.nih.gov/31215299/.

[87] SerenaGroup, Inc. A randomized controlled double-blind multicenter clinical trial evaluating remote ischemic conditioning (RIC) and standard of care vs sham therapy and standard care in the healing of diabetic foot ulcers. ClinicalTrials.gov Identifier: NCT04332003. Bethesda (MD): National Library of Medicine (US); 2021. Available from: https://clinicaltrials.gov/study/NCT04332003. Accessed November 28, 2025.

[88] Frush K. The physiological effects of remote ischemic conditioning on the healing of diabetic foot ulcers. ClinicalTrials.gov Identifier: NCT04567563. Bethesda (MD): National Library of Medicine (US); 2020. Available from: https://clinicaltrials.gov/study/NCT04567563. Accessed November 28, 2025.

[89] Xu X, Xu S, Gao Y, He S, He J, Chen X, et al. Remote ischemic conditioning slows blood-retinal barrier damage in type 1 diabetic rats. Brain Res 2025; 1846: 149253. https://doi.org/10.1016/j.brainres.2024.149253.

[90] Basalay MV, Davidson SM, Gourine AV, Yellon DM. Neural mechanisms in remote ischaemic conditioning in the heart and brain: mechanistic and translational aspects. Basic Res Cardiol 2018; 113: 25. https://doi.org/10.1007/s00395-018-0684-z.

[91] Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation 1997; 96: 1641-6. https://doi.org/10.1161/01.cir.96.5.1641.

[92] Penna C, Sorge M, Tullio F, Comità S, Femminò S, Brancaccio M, et al. A TRICk to improve the effectiveness of RIC: role of limb temperature in enhancing the effectiveness of remote ischemic conditioning. Biology (Basel) 2022; 11: 146. https://doi.org/10.3390/biology11010146.

[93] Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD. Myocardial protection by brief ischemia in noncardiac tissue. Circulation 1996; 94: 2193-200. https://doi.org/10.1161/01.cir.94.9.2193.

[94] Saxena P, Newman MAJ, Shehatha JS, Redington AN, Konstantinov IE. Remote ischemic conditioning: evolution of the concept, mechanisms, and clinical application. J Card Surg 2010; 25: 127-34. https://doi.org/10.1111/j.1540-8191.2009.00820.x.

[95] Mansour Z, Charles AL, Kindo M, Pottecher J, Chamaraux-Tran TN, Lejay A, et al. Remote effects of lower limb ischemia-reperfusion: impaired lung, unchanged liver, and stimulated kidney oxidative capacities. Biomed Res Int 2014; 2014: 392390. https://doi.org/10.1155/2014/392390.

[96] Joseph B, Khalil M, Hashmi A, Hecker L, Kulvatunyou N, Tang A, et al. Survival benefits of remote ischemic conditioning in sepsis. J Surg Res 2017; 213: 131-7. https://doi.org/10.1016/j.jss.2016.01.033.

[97] Liao MM, Chen S, Cao JR, Wang MW, Jin ZH, Ye J, et al. Early hemodynamics after tibial transverse transport in patients with nonarterial stenosis and arterial stenosis diabetic foot. World J Diabetes 2023; 14: 1784-92. https://doi.org/10.4239/wjd.v14.i12.1784.

[98] Zhao X, Liu L, Yuan Q, Shi Y, Zhang Y. Research progress of tibial transverse transport for diabetic foot. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2020; 34: 969-73. https://doi.org/10.7507/1002-1892.201911104.

[99] Li H, You J, Liu C, Ma Y. Effectiveness of transverse tibial bone transport in treatment of diabetic foot ulcer. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2019; 33: 23-7. https://doi.org/10.7507/1002-1892.201807143.

[100] Ou S, Wu X, Yang Y, Xia C, Zhang W, Qu Y, et al. Tibial cortex transverse transport potentiates diabetic wound healing via activation of SDF-1/CXCR4 signaling. PeerJ 2023; 11: e15894. https://doi.org/10.7717/peerj.15894.

[101] Zhen P, Chen Y, Gao W, Lin Z, Zhong Z, Teng Z, et al. The effectiveness of Ilizarov technique-based transverse tibial bone transport on treatment of severe diabetic foots complicated with systemic inflammation response syndrome. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2018; 32: 1261-6. https://doi.org/10.7507/1002-1892.201805024.

[102] Liu J, Huang X, Su H, Yu J, Nie X, Liu K, et al. Tibial cortex transverse transport facilitates severe diabetic foot wound healing via HIF-1 α-induced angiogenesis. J Inflamm Res 2024;Volume 17: 2681-96. https://doi.org/10.2147/JIR.S456590.

[103] Zeng Z, Dong Y, Hua Q, Kuang XC, Li K, Deng X, et al. Computed tomography perfusion study evaluating the curative effect of tibial transverse transport in patients with severe diabetic foot. J Orthop Translat 2019; 19: 133-42. https://doi.org/10.1016/j.jot.2019.04.005.

[104] Gan M, Xia X, You Y, Xu W, Peng X, Xu J, et al. Elevation and distraction of the tibial periosteum in the management of chronic ischemic lower limb diseases. J Orthop Surg (Hong Kong) 2024; 32: 10225536241295483. https://doi.org/10.1177/10225536241295483.

[105] Yuan Y, Ding X, Lu H, Chen Y, Xu H. A novel and alternative treatment method for moderate diabetic foot ulcer: tibial periosteal distraction. J Orthop Surg Res 2024; 19: 889. https://doi.org/10.1186/s13018-024-05375-7.

[106] Guan S, Du H, Wu Y, Qin S. The Ilizarov technique: a dynamic solution for orthopaedic challenges. Orthop Surg 2024; 16: 2111-4. https://doi.org/10.1111/os.14193.

[107] Chen P, You Y, Liu B, Zeng N, Zhong D. Tibial periosteum distraction for the treatment of lower extremity varicose vein ulcers combined with deep vein thrombosis: a case report. Medicine (Baltimore) 2025; 104: e45252. https://doi.org/10.1097/MD.0000000000045252.

[108] Schmidt BL, Kung L, Jones C, Casap N . Induced osteogenesis by periosteal distraction. J Oral Maxillofac Surg 2002; 60: 1170-5. https://doi.org/10.1053/joms.2002.34993.

[109] Casap N, Venezia NB, Wilensky A, Samuni Y. VEGF facilitates periosteal distraction-induced osteogenesis in rabbits: a micro-computerized tomography study. Tissue Eng Part A 2008; 14: 247-53. https://doi.org/10.1089/tea.2007.0069.

[110] Choi IH, Ahn JH, Chung CY, Cho TJ. Vascular proliferation and blood supply during distraction osteogenesis: a scanning electron microscopic observation. J Orthop Res 2000; 18: 698-705. https://doi.org/10.1002/jor.1100180504.

[111] Chang S, Zhang F, Chen W, Zhou J, Nie K, Deng C, et al. Outcomes of integrated surgical wound treatment mode based on tibial transverse transport for diabetic foot wound. Front Surg 2022; 9: 1051366. https://doi.org/10.3389/fsurg.2022.1051366.

[112] Noor S, Zubair M, Ahmad J. Diabetic foot ulcer-a review on pathophysiology, classification and microbial etiology. Diabetes Metab Syndr 2015; 9: 192- 9. https://doi.org/10.1016/j.dsx.2015.04.007.

[113] Sun Y, Zhou Y, Dai Y, Pan Y, Xiao Y, Yu Y. Predictors of post-healing recurrence in patients with diabetic foot ulcers: a systematic review and meta-analysis. J Tissue Viability 2024; 33: 542-9. https://doi.org/10.1016/j.jtv.2024.07.002.

[114] Boulton AJM, Whitehouse RW. The Diabetic Foot. Endotext [Internet]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK409609/. Accessed November 28, 2025.

[115] Rajkumar S, Venkatraman V, Zidanyue Yang L, Parente B, Lee HJ, Lad SP. Healthcare economics of high frequency spinal cord stimulation for painful diabetic peripheral neuropathy. J Diabetes Sci Technol 2024; 18: 635-43. https://doi.org/10.1177/19322968221128321.

[116] Deer T, Heros R, Scarfo K, Gilligan C, Jameson J, Pilitsis J, et al. A cost effectiveness analysis of spinal cord stimulation versus conventional medical management for the treatment of low back pain using data from DISTINCT RCT and medical claims from a U.S. Commercial Payer Database. J Pain Res 2025; 18: 2823-38. https://doi.org/10.2147/JPR.S486759.

[117] Coding & Payment Guides-Reimbursement. www.bostonscientific.com. Accessed November 28, 2025. https://www.bostonscientific.com/en-US/reimbursement/coding-and-payment-guides.html.

[118] ISPOR-Pain Therapy With Spinal Cord Stimulation (SCS) in Patients With Painful Diabetic Neuropathy (PDN): Results of a Budget Impact Model. Accessed November 28, 2025. https://www.ispor.org/heor-resources/presentations-database/presentation/euro2022-3564/120060.

[119] Wahezi SE, Yener U, Naeimi T, Lewis J, Yerra S, Sgobba P, et al. Spinal cord stimulation explantation and chronic pain: a systematic review and technology recommendations. J Pain Res 2025; 18: 1327-40. https://doi.org/10.2147/JPR.S514732.

[120] Taylor RS. Spinal cord stimulation in complex regional pain syndrome and refractory neuropathic back and leg pain/failed back surgery syndrome: results of a systematic review and meta-analysis. J Pain Symptom Manag 2006; 31: S13-9. https://doi.org/10.1016/j.jpainsymman.2005.12.010.

[121] Song JJ, Popescu A, Bell RL. Present and potential use of spinal cord stimulation to control chronic pain. Pain Physician 2014; 17: 235-46.

[122] West T, ElSaban M, Hussain N, Schappell J, Rogers K, Orhurhu V, et al. Incidence of lead migration with loss of efficacy or paresthesia coverage after spinal cord stimulator implantation: systematic review and proportional meta-analysis of prospective studies and randomized clinical trials. Neuromodulation 2023; 26: 917-27. https://doi.org/10.1016/j.neurom.2023.03.016.

[123] Dombovy-Johnson ML, D’Souza RS, Ha CT, Hagedorn JM. Incidence and risk factors for spinal cord stimulator lead migration with or without loss of efficacy: a retrospective review of 91 consecutive thoracic lead implants. Neuromodulation 2022; 25: 731-7. https://doi.org/10.1111/ner.13487.

[124] Liu K, Abulaiti A, Liu Y, Cai F, Ren P, Yusufu A. Risk factors of pin tract infection during bone transport using unilateral external fixator in the treatment of bone defects. BMC Surg 2021; 21: 377. https://doi.org/10.1186/s12893-021-01384-z.

[125] Feng D, Zhang Y, Jia H, Xu G, Wu W, Yang F, et al. Complications analysis of Ilizarov bone transport technique in the treatment of tibial bone defects-a retrospective study of 199 cases. BMC Musculoskelet Disord 2023; 24: 864. https://doi.org/10.1186/s12891-023-06955-0.

[126] Kukreja K, Reyaz S, Kumar MN. Outcome of bone transport using Ilizarov external fixator in infected non-union of tibia with large bone defects: comparison of those with 5-10 cm bone defect with those having ≥ 11 cm bone defect. Indian J Orthop 2024; 58: 345-53. https://doi.org/10.1007/s43465-024-01101-x.

[127] Nailing treatment in bone transport complications. Strategies in Trauma and Limb Reconstruction. Accessed November 28, 2025; 9: 89-96. https://link.springer.com/article/10.1007/s11751-014-0196-9.

[128] Emara KM, Allam MF. Ilizarov external fixation and then nailing in management of infected nonunions of the tibial shaft. J Trauma 2008; 65: 685-91. https://doi.org/10.1097/TA.0b013e3181569ecc.